New drug combo targets Hard-to-Treat cancers
NCT ID NCT06074497
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called KGX101, alone or with another drug (envafolimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see how the body processes the drug. About 54 participants will take part in this open-label study across multiple centers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peninsula & South Eastern Haematology and Oncology Group
Frankston, Victoria, 3199, Australia
-
Pindara Private Hospital
Benowa, Queensland, 4217, Australia
-
Sunshine Coast University Private Hospital
Birtinya, Queensland, 4575, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a dual protein blocker shrink Hard-to-Treat tumors?
- Can a new biologic boost the immune System's fight against advanced tumors?
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Experimental pill takes on advanced cancers alongside immunotherapy
- Smart T-Cell engager aims to outsmart tumors in first human test